Significant Agreements - Additional Information (Detail) - USD ($) $ in Millions		1 Months Ended	3 Months Ended
	Dec. 16, 2019	Feb. 28, 2021	Mar. 31, 2022
Takeda Asset Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront of cash payment	$ 1.0
Takeda Asset Agreement [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of Series A redeemable convertible preferred shares, shares	6,470,382
Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues			9,857,143
Stock Issued During Period, Value, New Issues	$ 9.9
Issuance of Series A redeemable convertible preferred shares, shares	9,857,143
Takeda Asset Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment			$ 8.0
Merck License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones			$ 367.0
Viracta License Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones		$ 54.0
Viracta License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of Milestones		$ 3.0
Upfront of cash payment	$ 2.0